ADTX Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeValuation
- Forward P/E
- 0.35
- PEG ratio
- —
- P/B
- 0.05
- P/S (TTM)
- 0.25
- EV/EBITDA
- 0.02
Profitability & growth
- ROE (TTM)
- -699.0%
- Operating margin
- -35874.0%
- Revenue growth YoY
- 1094.0%
- Dividend yield
- —
- Beta
- -17.50
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Aditxt Inc.
Company profileAditxt Inc. is an innovative biotechnology company dedicated to transforming healthcare through its proprietary immune modulation and personalized medicine platform. Focused on enhancing immune responses to address chronic diseases and allergies, Aditxt aims to significantly improve patient outcomes. With a robust pipeline of therapeutic candidates supported by comprehensive research and strategic collaborations, the company is poised to be a leader in the rapidly evolving field of immune-based therapies. Aditxt's commitment to scientific advancement and patient-centric solutions positions it…
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 2569 WYANDOTTE STREET, MOUNTAIN VIEW, CA
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer